Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience.

Background

Pirfenidone is an antifibrotic drug used for the treatment of idiopathic pulmonary fibrosis.

Objectives

The aim of this study was to evaluate the efficacy of pirfenidone in patients with chronic hypersensitivity pneumonitis (HP).

Methods

Twenty-three patients with chronic HP treated with pirfenidone were enrolled in this study based on a retrospective medical record review.

Results

The change in vital capacity (VC) in the 6 months after the start of treatment (-152±56.1 ml) was significantly improved compared with that in the 6 months before treatment (-292±77.8 ml, p=0.047). No patients discontinued the treatment with adverse events.

Conclusions

These results demonstrate that pirfenidone may reduce the decline of VC in patients with chronic HP without eliciting significant adverse events. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 139-142).